A Case of Nivolumab-Induced Myositis-Reference-Cited by-同舟云学术

A Case of Nivolumab-Induced Myositis

Published:2016-11-18 Issue:12 Volume:21 Page:e3-e3
ISSN:1083-7159
Container-title:The Oncologist
language:en
Short-container-title:

Author:

Fox Eric¹,Dabrow Michael²,Ochsner Greg²

Affiliation:

1. Lankenau Medical Center, Wynewood, Pennsylvania, USA

2. Paoli Hospital Cancer Center, Paoli, Pennsylvania, USA

Abstract

Nivolumab (Opdivo) is a monoclonal antibody classified as an immune modulator. A case is presented of nivolumab-induced myositis, an unlisted side effect.

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1634/theoncologist.2016-0170

Reference5 articles.

1. FDA approval summary: Nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy;Kazandjian;The Oncologist,2016

2. Nivolumab: A review of its use in patients with malignant melanoma;Deeks;Drugs,2014

3. Case of respiratory discomfort due to myositis after administration of nivolumab;Yoshioka;J Dermatol,2015

4. Mechanism of statin-induced rhabdomyolysis;Sakamoto;J Pharmacol Sci,2013

5. Anti-PD1 following ipilimumab for mucosal melanoma: Durable tumor response associated with severe hypothyroidism and rhabdomyolysis;Min;Cancer Immunol Res,2014

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy-Induced Eosinophilic Tracheitis;Cureus;2022-04-13

2. Incidence and Distinct Features of Immune Checkpoint Inhibitor-Related Myositis From Idiopathic Inflammatory Myositis: A Single-Center Experience With Systematic Literature Review and Meta-Analysis;Frontiers in Immunology;2021-12-06

3. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events;Journal for ImmunoTherapy of Cancer;2021-06

4. Phase I study of the antiprogrammed cell death‐1 Ab spartalizumab (PDR001) in Japanese patients with advanced malignancies;Cancer Science;2020-12-22

5. Statin Intolerance, Anti-HMGCR Antibodies, and Immune Checkpoint Inhibitor-Associated Myositis: A “Two-Hit” Autoimmune Toxicity or Clinical Predisposition?;The Oncologist;2020-06-03